Development

Agnes Shanley is senior editor of Pharmaceutical Technology.

Articles

Although continuous approaches offer significant benefits for some products and processes, batch manufacturing is not going away any time soon.

Continuous Manufacturing: Addressing the Tough Questions

Continuous manufacturing may offer huge opportunities, but it will not be right for
every facility or product.


Batch or Continuous? Ask the Right Questions During Scale Up

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

New technologies in the digital factory enhance quality, efficiency, and flexibility for bio/pharmaceutical manufacturing.

Embracing the Digital Factory for Bio/Pharma Manufacturing

Guillame Plane is global development and marketing manager for  MilliporeSigma's BioReliance End-to-End Solutions.

Only careful planning can prevent problems that stem from differences between a sponsor’s and a CDMO’s equipment, practices, and culture. This article highlights best practices and case studies.

A Systematic Approach to Tech Transfer and Scale-Up

Boehringer Ingelheim plans to develop and test new strategies at its Solids Launch facility.

Scaling Up and Launching Solid-Dosage Drugs

Once described as “throwing processes over the wall,” tech transfer is evolving into close collaboration and communication, as potential problems are considered sooner, and new technology is applied. Joseph Szczesiul, director of technical services for UPM Pharmaceuticals, shares best practices.

Tech Transfer: Tearing Down the Wall

The new center will integrate biologics drug discovery, development, clinical manufacturing, and commercial manufacturing.

WuXi Biologics Begins Construction of Major Biologics Center in China

The CHF 400-million (US$416-million) investment in Lonza's biopark in Visp, Switzerland, will expand Ibex Solutions with two new offerings, drug substance development and drug substance and drug product manufacturing.

Lonza Expands Product Lifecycle Management Capabilities

The new Testa Center in Uppsala, Sweden is a collaborative test bed offering biotechnology equipment from GE Healthcare for process development. 

Swedish Government and GE Healthcare Open an Innovation Center for Life Sciences

The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.